Aurinia Pharmaceuticals Inc
AUPHHealthcare|Biotechnology|Canada
$15.79
-0.81 (-4.88%)
DCF (FCF)
$1.77
Tangible Book
$4.31
Graham Number
$14.51
Financials
Financial Snapshot
Market Cap
$2.03B
Enterprise Value
$310.1M
Revenue (TTM)
$298.3M
Net Income (TTM)
$298.2M
Cash & Equivalents
—
Net Cash/Share
$1.70
Free Cash Flow (TTM)
$166.6M
Operating CF (TTM)
$166.9M
Debt/Equity
0.12
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $39.6M | $173.5M | $125.9M | $306.0M | $398.3M | $466.1M | $389.4M | $350.5M | $358.5M | $398.0M | $378.8M | |
| Operating Cash Flow | $-18.7M | $-41.2M | $-51.6M | $-63.6M | $-69.9M | $-157.7M | $-79.5M | $-33.5M | $44.4M | $135.7M | $166.9M | |
| Free Cash Flow | $-18.7M | $-41.2M | $-51.7M | $-63.7M | $-77.2M | $-159.2M | $-79.8M | $-34.2M | $44.1M | $135.4M | $166.6M | |
| Capital Expenditure | $-25.0K | $-25.0K | $-74.0K | $-101.0K | $-7.3M | $-1.5M | $-292.0K | $-718.0K | $-281.0K | $-252.0K | $-274.0K | |
| Financing Cash Flow | $42.6M | $175.2M | $4.0M | $243.9M | $194.4M | $221.1M | $2.4M | $-5.1M | $-49.1M | $-106.1M | $-110.5M |
R&D Spending
R&D (TTM)
$34.2M
R&D Intensity
11.5%
R&D Growth YoY
+5.3%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $173.0K | $418.0K | $463.0K | $318.0K | $50.1M | $45.6M | $134.0M | $175.5M | $235.1M | $283.1M | $298.3M | |
| R&D Expense | $14.5M | $33.9M | $41.4M | $52.9M | $50.3M | $51.1M | $45.0M | $49.6M | $20.8M | $32.5M | $34.2M | |
| R&D % of Revenue | 8401.2% | 8117.2% | 8937.8% | 16624.5% | 100.4% | 112.1% | 33.6% | 28.3% | 8.8% | 11.5% | 11.5% | |
| SG&A | $7.0M | $12.1M | $13.7M | $22.3M | $97.3M | $173.5M | $196.4M | $195.0M | $172.0M | $101.8M | $103.5M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $173.0K | $418.0K | $463.0K | $318.0K | $50.1M | $45.6M | $134.0M | $175.5M | $235.1M | $283.1M | $298.3M | |
| Cost of Goods Sold | $4.0K | $-1.0K | $0.00 | $0.00 | $0.00 | $1.1M | $5.7M | $14.1M | $28.2M | $32.7M | $30.6M | |
| Gross Profit | $169.0K | $419.0K | $463.0K | $318.0K | $50.1M | $44.5M | $128.4M | $161.4M | $206.9M | $250.4M | $267.7M | |
| R&D | $14.5M | $33.9M | $41.4M | $52.9M | $50.3M | $51.1M | $45.0M | $49.6M | $20.8M | $32.5M | $34.2M | |
| SG&A | $7.0M | $12.1M | $13.7M | $22.3M | $97.3M | $173.5M | $196.4M | $195.0M | $172.0M | $101.8M | $103.5M | |
| Operating Income | $-22.8M | $-47.1M | $-55.9M | $-90.9M | $-104.3M | $-180.7M | $-111.5M | $-91.7M | $18.4M | $106.6M | $124.6M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $-39.0K | $0.00 | $0.00 | $0.00 | $-2.8M | $-4.8M | $-4.3M | $-4.3M | |
| Pretax Income | $-23.3M | $-70.8M | $-53.0M | $-88.2M | $-102.8M | $-180.2M | $-106.4M | $-77.5M | $7.4M | $114.2M | $133.7M | |
| Net Income | $-23.3M | $-70.8M | $-53.1M | $-88.4M | $-102.7M | $-181.0M | $-108.2M | $-78.0M | $5.8M | $287.2M | $298.2M | |
| EPS (Diluted) | -0.66 | -0.92 | -0.63 | -0.95 | -0.87 | -1.40 | -0.76 | -0.54 | 0.04 | 2.07 | 2.17 | |
| EBITDA | $-21.3M | $-45.6M | $-54.6M | $-89.8M | $-102.9M | $-177.4M | $-103.6M | $-63.0M | $31.7M | $137.9M | $157.4M | |
| Shares Out. (M) | 35.28 | 76.92 | 84.78 | 93.02 | 118.47 | 129.37 | 141.91 | 143.24 | 146.19 | 138.70 | 137.64 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $39.6M | $165.6M | $118.0M | $306.0M | $272.4M | $231.9M | $94.2M | $48.9M | $83.4M | $80.2M | $41.0M | |
| Marketable Securities | $0.00 | $7.8M | $7.9M | $0.00 | $126.0M | $234.2M | $295.2M | $301.6M | $275.0M | $317.8M | $337.8M | |
| Total Current Assets | $41.4M | $175.3M | $132.8M | $315.1M | $419.4M | $513.3M | $442.5M | $424.8M | $446.6M | $492.0M | $480.2M | |
| Total Assets | $57.0M | $189.8M | $145.9M | $324.3M | $463.7M | $543.4M | $470.9M | $548.1M | $550.6M | $751.6M | $724.0M | |
| Total Current Liabilities | $7.9M | $8.2M | $7.3M | $11.3M | $32.0M | $40.6M | $46.1M | $77.2M | $97.8M | $93.7M | $86.6M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $21.0M | $24.1M | $33.3M | $25.7M | $55.9M | $64.3M | $65.4M | $170.1M | $173.2M | $170.3M | $156.4M | |
| Stockholders' Equity | $36.0M | $165.7M | $112.6M | $298.6M | $407.8M | $479.1M | $405.4M | $378.0M | $377.5M | $581.3M | $567.6M | |
| Retained Earnings | $-281.0M | $-351.8M | $-416.0M | $-472.5M | $-575.2M | $-756.1M | $-864.3M | $-942.3M | $-936.6M | $-649.4M | $-615.0M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-18.7M | $-41.2M | $-51.6M | $-63.6M | $-69.9M | $-157.7M | $-79.5M | $-33.5M | $44.4M | $135.7M | $166.9M | |
| Capital Expenditure | $-25.0K | $-25.0K | $-74.0K | $-101.0K | $-7.3M | $-1.5M | $-292.0K | $-718.0K | $-281.0K | $-252.0K | $-274.0K | |
| Free Cash Flow | $-18.7M | $-41.2M | $-51.7M | $-63.7M | $-77.2M | $-159.2M | $-79.8M | $-34.2M | $44.1M | $135.4M | $166.6M | |
| Investing Cash Flow | $10.0M | $-8.0M | $-65.0K | $7.8M | $-158.2M | $-103.9M | $-60.6M | $-6.7M | $39.3M | $-32.8M | $-81.9M | |
| Financing Cash Flow | $42.6M | $175.2M | $4.0M | $243.9M | $194.4M | $221.1M | $2.4M | $-5.1M | $-49.1M | $-106.1M | $-110.5M | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $223.1M | $187.7M | $196.7M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Repurchase of Stock | $7.8M | $162.3M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-40.2M | $-98.2M | $-87.4M | |
| Issuance of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $0.00 | $0.00 | $0.00 | $-127.0K | $0.00 | $0.00 | $0.00 | $-10.0M | $-12.0M | $-13.1M | $-14.0M | |
| Stock Based Comp. | $1.4M | $4.2M | $6.9M | $7.4M | $17.5M | $31.2M | $32.3M | $45.3M | $31.6M | $14.7M | $17.2M | |
| Net Change in Cash | $33.9M | $126.0M | $-47.7M | $188.1M | $-33.7M | $-40.5M | $-137.7M | $-45.3M | $34.6M | $-3.2M | $-25.4M |
Dilution Tracker
Shares Outstanding
138M
5-Year Share Growth
+6.4%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 35.28 | 76.92 | 84.78 | 93.02 | 118.47 | 129.37 | 141.91 | 143.24 | 146.19 | 138.70 | 137.64 | |
| YoY Change % | — | 118.0% | 10.2% | 9.7% | 27.4% | 9.2% | 9.7% | 0.9% | 2.1% | -5.1% | -0.8% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $223.1M | $187.7M | $196.7M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Repurchase | $7.8M | $162.3M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-40.2M | $-98.2M | $-87.4M | |
| Stock Based Comp. | $1.4M | $4.2M | $6.9M | $7.4M | $17.5M | $31.2M | $32.3M | $45.3M | $31.6M | $14.7M | $17.2M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 97.7% | 100.2% | 0.0% | 0.0% | 0.0% | 97.6% | 95.8% | 91.9% | 88.0% | 88.5% | 89.7% | |
| Operating Margin % | -13187.3% | -11259.3% | -12074.7% | -28598.4% | -208.1% | -396.3% | -83.2% | -52.2% | 7.8% | 37.6% | 41.8% | |
| Net Margin % | -13465.3% | -16935.9% | -11464.1% | -27794.0% | -204.9% | -396.8% | -80.7% | -44.5% | 2.4% | 101.5% | 100.0% | |
| EBITDA Margin % | -12332.4% | -10911.0% | -11791.1% | -28230.2% | -205.4% | -389.1% | -77.3% | -35.9% | 13.5% | 48.7% | 52.8% | |
| FCF Margin % | -10831.2% | -9855.0% | -11163.1% | -20027.0% | -154.0% | -349.1% | -59.6% | -19.5% | 18.8% | 47.8% | 55.9% | |
| ROE % | -83.3% | -70.2% | -38.1% | -43.0% | -29.1% | -40.8% | -24.5% | -19.9% | 1.5% | 59.9% | 67.8% | |
| ROA % | -51.4% | -57.4% | -31.6% | -37.6% | -26.1% | -35.9% | -21.3% | -15.3% | 1.0% | 44.1% | 49.5% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)7.28
Historical6.71 / 26.45 / 170.80
Industry Med.27.41
P/S7.27
Historical3.68 / 36.17 / 10710.00
Industry Med.9.51
P/B3.64
Historical1.45 / 3.64 / 16.33
Industry Med.2.93
EV/EBITDA10.93
Historical-35.12 / -7.80 / 251.45
Industry Med.13.14
EV/Revenue5.77
Historical1.89 / 30.99 / 5786.47
Industry Med.8.71
P/FCF13.01
Historical11.73 / 18.23 / 48.05
Industry Med.27.54
Intrinsic Value Models
DCF (FCF Based)
$1.77
Tangible Book
$4.31
Net Current Assets
$2.480
Graham Number
$14.51
Net-Net Working Capital
$2.16
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | 224.50 | 7.71 | 7.28 | |
| PS Ratio | 420.00 | 906.00 | 1364.00 | 6753.33 | 32.70 | 64.79 | 4.58 | 7.34 | 5.58 | 7.81 | 7.27 | |
| PB Ratio | 3.08 | 2.30 | 5.18 | 7.59 | 4.30 | 6.76 | 1.52 | 3.42 | 3.35 | 3.63 | 3.64 | |
| EV/EBITDA | -3.34 | -4.55 | -8.38 | -21.82 | -13.24 | -15.67 | -2.25 | -16.50 | 31.08 | 12.96 | 10.93 | |
| EV/Revenue | 411.84 | 495.92 | 987.59 | 6160.40 | 27.19 | 60.98 | 1.74 | 5.93 | 4.19 | 6.31 | 5.77 |
Analyst Estimates & Quality
Altman Z-Score
8.30
Safe
Piotroski F-Score
7
Strong
Beneish M-Score
7.94
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $323.1M | $384.0M | $452.4M |
| Net Income | $129.4M | $161.5M | $206.4M |
| EPS | 1.02 | 1.22 | 1.52 |
| Book Value per Share | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow per Share | 1.24 | 1.81 | 1.64 |
| Operating CF | $170.67M | $249.13M | $225.73M |
Dividends
Revenue Segments
By Business
| Segment | 2025 |
|---|---|
| Single Segment | $283.1M |
By Geography
| Segment | 2025 |
|---|---|
| United States | $263.8M |
| Japan | $19.2M |